Welcome to our dedicated page for Grifols SEC filings (Ticker: GIFLF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GIFLF SEC filings page on Stock Titan provides access to U.S. regulatory documents for Grifols, S.A., a foreign private issuer and global healthcare company focused on plasma‑derived medicines and transfusion medicine. Grifols files with the U.S. Securities and Exchange Commission under Commission File No. 001‑35193, primarily through annual reports on Form 20‑F and current reports on Form 6‑K.
Through these filings, investors can review information on Grifols’ financial performance, including quarterly results releases and earnings presentations that discuss revenue, profit, cash flow generation, leverage ratios, and alternative performance measures such as adjusted EBITDA, as defined in the company’s investor materials. The filings also describe the performance of its biopharma and diagnostic activities, and its focus on therapeutic areas such as immunology, infectious diseases, pulmonology, and critical care.
Regulatory and operational milestones are documented in Form 6‑K submissions. Examples include the European Medicines Agency’s certificate of compliance for plasma supplied by Grifols Egypt for Plasma Derivatives, confirming adherence to European quality and safety standards, and governance updates such as the creation of a Strategy Committee or changes in board secretary and vice‑secretary roles.
Stock Titan enhances these filings with AI-powered summaries that highlight key points and help explain complex sections of lengthy documents. Users can quickly identify important topics in 20‑F and 6‑K reports, while still having direct access to the full text from EDGAR. The page also surfaces filing dates and types so that investors researching GIFLF can efficiently follow Grifols’ regulatory history, corporate actions, and ongoing disclosure practices.
Grifols, S.A. reports that its Board of Directors has decided to start a process to evaluate a potential Initial Public Offering in the United States of a portion of the shares of its subsidiary that is the parent of its U.S. Biopharma business. The company stresses that any IPO would depend on regulatory and legal requirements, internal approvals and market conditions, and there is no assurance that it will be undertaken or completed. Grifols also notes that, regardless of whether any IPO occurs, its shares will continue trading in Spain on the mercado continuo, and this communication does not constitute an offer or solicitation to buy or sell securities.
Grifols, S.A. reported strong FY2025 results, with net revenue of EUR 7,524 million, up 7.0% at constant currency, led by Biopharma and particularly its immunoglobulin franchise. Adjusted EBITDA reached EUR 1,825 million, growing 5.6% at constant currency and 11.9% like-for-like, for a 24.3% margin.
Net profit attributable to the parent more than doubled to EUR 402 million from EUR 157 million in 2024, helped by a higher operating margin and lower financial costs. Free cash flow pre-M&A improved to EUR 468 million, up EUR 201 million, reflecting better working capital, lower interest and normalized capex.
The leverage ratio fell from 4.6x to 4.2x, and all three major rating agencies upgraded or improved outlooks on Grifols’ credit ratings. Management targets 2026 free cash flow pre-M&A pre-dividends of EUR 500–575 million, an Adjusted EBITDA margin of at least 25% with 5–9% constant-currency EBITDA growth, and confirms 2027 goals of leverage at or below 3.5x and cumulative 2024–2027 free cash flow of EUR 1.75–2.0 billion.
Permian Investment Partners and affiliated funds reported beneficial ownership of 18,607,262 Grifols Class B shares, equal to 7.1% of the class. The holdings are spread across several Permian funds and managed accounts, including ADRs and ordinary shares.
The ownership percentages are based on 261,425,110 Class B shares outstanding as of December 31, 2024, as disclosed in Grifols’ Form 20-F. The filers certify the securities were not acquired to change or influence control of Grifols.
Brandes Investment Partners, L.P. has filed an amended Schedule 13G reporting a significant passive ownership position in Grifols SA common shares. The investment adviser reports beneficial ownership of 20.67% of the class, indicating it controls a large block of the company’s equity.
Brandes reports no sole voting or dispositive power over these shares and instead lists only shared dispositive power, meaning decisions to sell or otherwise dispose are made in a shared capacity. The filing also certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Grifols.
Grifols, S.A. reports a change in its Board support roles. The Board of Directors unanimously approved, with effect from 1 January 2026, the appointment of Ms. Laura de la Cruz Galán as the new Secretary non-member of the Board of Directors, replacing Mrs. Núria Martín Barnés. At the same time, Mrs. Núria Martín Barnés has been appointed as the new Vice-secretary non-member of the Board of Directors, replacing Ms. Laura de la Cruz Galán. The decision followed a favourable report from the Appointments and Remuneration Committee.
Grifols, S.A. reports that the European Medicines Agency (EMA) has issued a Certificate of Compliance with Community legislation for plasma supplied by Grifols Egypt for Plasma Derivatives (GEPD), the joint venture created in 2020 with Egypt’s National Service Projects Organization. This certification follows EMA inspection of GEPD’s plasma centers and verification that donor selection, plasma collection, quality controls, and storage meet European quality and safety standards.
The EMA certification allows GEPD not only to manufacture plasma-derived products but also to commercialize them throughout Europe and in countries that follow EMA legislation. Grifols describes this as a huge milestone, noting it is the first plasma company to achieve this step for Egyptian plasma, and that it positions Egypt as the first country in Africa and the Middle East with a fully integrated plasma collection and processing system meeting these strict international standards.
Brandes Investment Partners, L.P. filed an amended Schedule 13G reporting beneficial ownership in Grifols SA. As of 09/30/2025, Brandes reports beneficial ownership of 29,126,291.55 ADRs, representing 19.6% of the class.
The filer reports no sole or shared voting power and shared dispositive power over 29,126,291.55 ADRs. Item 4 also notes holdings of 22,107,370 ordinary shares and 29,126,291.55 ADRs for which dispositive power is shared. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Grifols (GRFS) reported Q3 2025 results with revenue of EUR 1,865 million and quarterly group profit of EUR 127 million, reflecting strong momentum in its Value Creation Plan. Year-to-date revenues reached EUR 5,542 million, up 7.7% at constant currency, while adjusted EBITDA was EUR 1,358 million with a 24.5% margin. Q3 adjusted EBITDA was EUR 482 million, up 8.8% at constant currency, with a 25.8% margin.
Year-to-date net profit was EUR 304 million, up 245%. Free cash flow pre-M&A and pre-dividend was EUR 203 million in Q3, bringing the nine-month total to EUR 188 million, a EUR 257 million improvement versus last year. Leverage improved to 4.2x from 5.1x a year ago, and liquidity rose to EUR 1,475 million.
Growth was led by Biopharma, with a 9.1% constant-currency increase year-to-date and 10.9% in Q3. Immunoglobulin revenues rose 14.4% year-to-date, while subcutaneous IG grew more than 60%. Albumin declined 3.9% year-to-date due to pricing adjustments in China. The Diagnostic business generated EUR 479 million year-to-date, up 1.4%, with FDA approval to begin manufacturing Gel Cards and reagent Red Blood Cells in San Diego. Grifols noted potential full-year FX headwinds of approximately EUR 70 million to adjusted EBITDA if current rates persist.
Grifols, S.A. notified that on September 29, 2025 the Board established a Strategy Committee with an advisory role to assist the Board of Directors and to make proposals on strategic initiatives and developments. The notice states the committee's specific authorities are set out in the Board's Internal Functioning Regulations and the Strategy Committee's own Regulations. The company also amended those Internal Functioning Regulations to formally allocate authorities to the new Strategy Committee. The report is signed by Nuria Martín Barnés as Secretary to the Board and by David I. Bell as Authorized Signatory.